Works matching IS 13479032 AND DT 2023 AND VI 114 AND IP 2
Results: 32
Proteolytic cleavage of membrane proteins by membrane type‐1 MMP regulates cancer malignant progression.
- Published in:
- Cancer Science, 2023, v. 114, n. 2, p. 348, doi. 10.1111/cas.15638
- By:
- Publication type:
- Article
Sialylated IgG in epithelial cancers inhibits antitumor function of T cells via Siglec‐7.
- Published in:
- Cancer Science, 2023, v. 114, n. 2, p. 370, doi. 10.1111/cas.15631
- By:
- Publication type:
- Article
Ror1 is expressed inducibly by Notch and hypoxia signaling and regulates stem cell‐like property of glioblastoma cells.
- Published in:
- Cancer Science, 2023, v. 114, n. 2, p. 561, doi. 10.1111/cas.15630
- By:
- Publication type:
- Article
Serum untargeted metabolomics reveal metabolic alteration of non‐small cell lung cancer and refine disease detection.
- Published in:
- Cancer Science, 2023, v. 114, n. 2, p. 680, doi. 10.1111/cas.15629
- By:
- Publication type:
- Article
Engulfment and cell motility protein 1 fosters reprogramming of tumor‐associated macrophages in colorectal cancer.
- Published in:
- Cancer Science, 2023, v. 114, n. 2, p. 410, doi. 10.1111/cas.15628
- By:
- Publication type:
- Article
Diallyl trisulfide alleviates chemotherapy sensitivity of ovarian cancer via the AMPK/SIRT1/PGC1α pathway.
- Published in:
- Cancer Science, 2023, v. 114, n. 2, p. 357, doi. 10.1111/cas.15627
- By:
- Publication type:
- Article
BMI‐1 promotes breast cancer proliferation and metastasis through different mechanisms in different subtypes.
- Published in:
- Cancer Science, 2023, v. 114, n. 2, p. 449, doi. 10.1111/cas.15623
- By:
- Publication type:
- Article
Yes‐associated protein 1 mediates initial cell survival during lorlatinib treatment through AKT signaling in ROS1‐rearranged lung cancer.
- Published in:
- Cancer Science, 2023, v. 114, n. 2, p. 546, doi. 10.1111/cas.15622
- By:
- Publication type:
- Article
Nivolumab‐induced radiation recall pneumonitis in non‐small‐cell lung cancer patients with thoracic radiation therapy.
- Published in:
- Cancer Science, 2023, v. 114, n. 2, p. 630, doi. 10.1111/cas.15621
- By:
- Publication type:
- Article
S‐1 eliminates MDSCs and enhances the efficacy of PD‐1 blockade via regulation of tumor‐derived Bv8 and S100A8 in thoracic tumor.
- Published in:
- Cancer Science, 2023, v. 114, n. 2, p. 384, doi. 10.1111/cas.15620
- By:
- Publication type:
- Article
Mitogen‐activated protein kinase inhibition augments the T cell response against HOXB7‐expressing tumor through human leukocyte antigen upregulation.
- Published in:
- Cancer Science, 2023, v. 114, n. 2, p. 399, doi. 10.1111/cas.15619
- By:
- Publication type:
- Article
SUMOylation of TUFT1 is essential for gastric cancer progression through AKT/mTOR signaling pathway activation.
- Published in:
- Cancer Science, 2023, v. 114, n. 2, p. 533, doi. 10.1111/cas.15618
- By:
- Publication type:
- Article
TAS2940, a novel brain‐penetrable pan‐ERBB inhibitor, for tumors with HER2 and EGFR aberrations.
- Published in:
- Cancer Science, 2023, v. 114, n. 2, p. 654, doi. 10.1111/cas.15617
- By:
- Publication type:
- Article
Intraoperative rapid immunohistochemistry with noncontact antibody mixing for undiagnosed pulmonary tumors.
- Published in:
- Cancer Science, 2023, v. 114, n. 2, p. 702, doi. 10.1111/cas.15616
- By:
- Publication type:
- Article
Identification of a novel target of SETD1A histone methyltransferase and the clinical significance in pancreatic cancer.
- Published in:
- Cancer Science, 2023, v. 114, n. 2, p. 463, doi. 10.1111/cas.15615
- By:
- Publication type:
- Article
circTOP2A functions as a ceRNA to promote glioma progression by upregulating RPN2.
- Published in:
- Cancer Science, 2023, v. 114, n. 2, p. 490, doi. 10.1111/cas.15612
- By:
- Publication type:
- Article
Phase I trial of myeloablative conditioning with 3‐day total marrow and lymphoid irradiation for leukemia.
- Published in:
- Cancer Science, 2023, v. 114, n. 2, p. 596, doi. 10.1111/cas.15611
- By:
- Publication type:
- Article
Hepatic stellate cell‐released CXCL1 aggravates HCC malignant behaviors through the MIR4435‐2HG/miR‐506‐3p/TGFB1 axis.
- Published in:
- Cancer Science, 2023, v. 114, n. 2, p. 504, doi. 10.1111/cas.15605
- By:
- Publication type:
- Article
Metformin and simvastatin synergistically suppress endothelin 1‐induced hypoxia and angiogenesis in multiple cancer types.
- Published in:
- Cancer Science, 2023, v. 114, n. 2, p. 640, doi. 10.1111/cas.15602
- By:
- Publication type:
- Article
Survival prediction of stomach cancer using expression data and deep learning models with histopathological images.
- Published in:
- Cancer Science, 2023, v. 114, n. 2, p. 690, doi. 10.1111/cas.15592
- By:
- Publication type:
- Article
Correction.
- Published in:
- Cancer Science, 2023, v. 114, n. 2, p. 712, doi. 10.1111/cas.15589
- Publication type:
- Article
Vimentin and tumor–stroma ratio for neoadjuvant chemoradiotherapy response prediction in locally advanced rectal cancer.
- Published in:
- Cancer Science, 2023, v. 114, n. 2, p. 619, doi. 10.1111/cas.15610
- By:
- Publication type:
- Article
Phase I study of the irreversible fibroblast growth factor receptor 1–4 inhibitor futibatinib in Japanese patients with advanced solid tumors.
- Published in:
- Cancer Science, 2023, v. 114, n. 2, p. 574, doi. 10.1111/cas.15486
- By:
- Publication type:
- Article
High levels of AXL expression in untreated EGFR‐mutated non‐small cell lung cancer negatively impacts the use of osimertinib.
- Published in:
- Cancer Science, 2023, v. 114, n. 2, p. 606, doi. 10.1111/cas.15608
- By:
- Publication type:
- Article
BACH1 promotes clear cell renal cell carcinoma progression by upregulating oxidative stress‐related tumorigenicity.
- Published in:
- Cancer Science, 2023, v. 114, n. 2, p. 436, doi. 10.1111/cas.15607
- By:
- Publication type:
- Article
Molecular subtyping of small‐cell lung cancer based on mutational signatures with different genomic features and therapeutic strategies.
- Published in:
- Cancer Science, 2023, v. 114, n. 2, p. 665, doi. 10.1111/cas.15606
- By:
- Publication type:
- Article
SREBF2–STARD4 axis confers sorafenib resistance in hepatocellular carcinoma by regulating mitochondrial cholesterol homeostasis.
- Published in:
- Cancer Science, 2023, v. 114, n. 2, p. 477, doi. 10.1111/cas.15449
- By:
- Publication type:
- Article
UBE2T promotes glioblastoma malignancy through ubiquitination‐mediated degradation of RPL6.
- Published in:
- Cancer Science, 2023, v. 114, n. 2, p. 521, doi. 10.1111/cas.15604
- By:
- Publication type:
- Article
Attenuated humoral response against SARS‐CoV‐2 mRNA vaccination in allogeneic stem cell transplantation recipients.
- Published in:
- Cancer Science, 2023, v. 114, n. 2, p. 586, doi. 10.1111/cas.15603
- By:
- Publication type:
- Article
In this issue: Volume 114, Issue 2, February 2023.
- Published in:
- Cancer Science, 2023, v. 114, n. 2, p. 345, doi. 10.1111/cas.15406
- Publication type:
- Article
Issue Information.
- Published in:
- Cancer Science, 2023, v. 114, n. 2, p. 341, doi. 10.1111/cas.15405
- Publication type:
- Article
Matrix metalloproteinase‐21 promotes metastasis via increasing the recruitment and M2 polarization of macrophages in HCC.
- Published in:
- Cancer Science, 2023, v. 114, n. 2, p. 423, doi. 10.1111/cas.15368
- By:
- Publication type:
- Article